Evidence map›Paper›PMID 14561889›Full record

ArticleRNA (New York, N.Y.)2003

Association of polyadenylation cleavage factor I with U1 snRNP.

Sita Awasthi, James C Alwine

Open access · bronzeAbstract read
In one paragraph

Article in RNA (New York, N.Y.), 2003. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 36 papers.

0numbers the graph read from it
0cells of the map it votes in
36citing papers in PubMed
0.5field-weighted citation impact, top 38% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

36 citing papers in PubMed, 65 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Review
  10. Alternative Polyadenylation: Methods, Findings, and Impacts.Genomics, proteomics & bioinformatics · 2017
    Review
  11. Article
  12. Article
  13. Article
  14. The reciprocal regulation between splicing and 3'-end processing.Wiley interdisciplinary reviews. RNA · 2016
    Review
  15. Article
  16. Review
  17. A critical role for alternative polyadenylation factor CPSF6 in targeting HIV-1 integration to transcriptionally active chromatin.Proceedings of the National Academy of Sciences of the United States of America · 2016
    Article
  18. Article
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

2 authors at 1 institution in 1 country.

Sita AwasthiDepartment of Cancer Biology, Abramson Family Cancer Research Institute, University of Pennsylvania, School of Medicine, Philadelphia, Pennsylvania 19104-6142, USA.
James C Alwine
Cancer Research Institute · US

Funding

MECHANISMS OF POLYADENYLATION IN VIRAL SYSTEMSR01GM045773 · NIGMS · UNIVERSITY OF PENNSYLVANIA · PI ALWINE, JAMES C · 1991 to 2008
$2.3M
NIGMS NIH HHS GM45773NIGMS NIH HHS R01 GM045773
6 · The paper itself

Abstract

Splicing and polyadenylation factors interact for the control of polyadenylation and the coupling of splicing and polyadenylation. We document an interaction between the U1 snRNP and mammalian polyadenylation cleavage factor I (CF Im), one of several polyadenylation factors needed for the cleavage of the pre-mRNA at the polyadenylation site. Sucrose density gradient centrifugation demonstrated that CF Im separated into two fractions, a light fraction which contained the known CF Im subunits (72, 68, 59, and 25 kD), and a heavy fraction, rich in snRNPs, which contained predominately the 68- and 25-kD CF Im subunits. Using specific antibodies we found that the heavy fraction contains U1 snRNP/CF Im coprecipitable complexes. These complexes were insensitive to RNase treatment, suggesting that the coprecipitation is not due to RNA tethering. In vitro binding experiments show that both the 68- and 25-kD subunits bind to and comigrate with U1 snRNP. In addition, the 25-kD CF Im subunit binds specifically to the 70K protein of U1 snRNP (U1 70K). This binding may account for the CF Im/U1 snRNP interaction. During these studies we found that mAb 2.73 (mAb 2.73), an established U1 70K antibody, efficiently precipitates the bulk of the CF Im from cellular extracts. Because mAb 2.73 has been used in a number of previous studies related to the U1 snRNP and the U1 70K protein, the precipitation of CF Im must be considered in evaluating past and future data based on the use of mAb 2.73.

Indexed as

HydrolysismRNA Cleavage and Polyadenylation FactorsPrecipitin TestsProtein BindingRibonucleoprotein, U1 Small NuclearmRNA Cleavage and Polyadenylation FactorsRibonucleoprotein, U1 Small Nuclear

Identifiers

PMID14561889
PMCPMC1287061
OpenAlexW2138717326

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.